- Research article
- Open Access
Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer
BMC Cancer volume 16, Article number: 354 (2016)
It has been shown that epidermal growth factor receptor (EGFR) mutation status is associated with 5-fluorouracil (5-FU) sensitivity in non-small-cell lung cancer (NSCLC). However, the relationship between EGFR mutation status and dihydropyrimidine dehydrogenase (DPD), a 5-FU degrading enzyme, is unknown.
We elucidated the crosstalk among the EGFR signal cascade, the DPD gene (DPYD), and DPD protein expression via the transcription factor Sp1 and the effect of EGFR mutation status on the crosstalk.
In the PC9 (exon19 E746-A750) study, EGF treatment induced up-regulation of both Sp1 and DPD; gefitinib, an EGFR-tyrosine kinase inhibitor (EGFR-TKI), and mithramycin A, a specific Sp-1 inhibitor, suppressed them. Among EGFR-mutated (PC9, HCC827; exon19 E746-A750 and H1975; exon21 L858R, T790M, gefitinib resistant) and -non-mutated (H1437, H1299) cell lines, EGF administration increased DPYD mRNA expression only in mutated cells (p < 0.05). Accordingly, gefitinib inhibited DPD protein expression only in PC9 and HCC827 cells, and mithramycin A inhibited it in EGFR-mutated cell lines, but not in wild-type. FU treatment decreased the level of cell viability more in gefitinib-treated EGFR-TKI sensitive cell lines. Further, combination treatment of FU and mithramycin A suppressed cell viability even in a gefitinib resistant cell line.
The EGFR signal cascade regulates DPD expression via Sp1 in EGFR mutant cells. These results might be a step towards new therapies targeting Sp1 and DPD in NSCLC with different EGFR mutant status.
The epidermal growth factor receptor (EGFR) is highly expressed in cancer cells, including non-small-cell lung cancer (NSCLC). Molecular-targeted therapy by EGFR tyrosine kinase inhibitor (EGFR-TKI) has altered the treatment regimen of NSCLC. In vitro and clinical studies have indicated predictive factors associated with the response and survival benefit of EGFR-TKI, including gefitinib, and higher response populations are observed in East Asians, non-smokers, females, and adenocarcinoma (ADC) patients [1–4]. A combination analysis of a Japanese phase II study found that NSCLC patients with EGFR mutations have higher response rates for EGFR-TKI . Several randomized studies have also revealed that reversible EGFR-TKIs such as erlotinib and gefitinib are superior to standard chemotherapy with regard to progression-free survival, as well as progression-free survival in patients with NSCLC with EGFR sensitive mutations [6–10]. However, primary or acquired resistance limits the therapeutic success of these targeted agents [11, 12]. An irreversible inhibitor of afatinib has been developed to confer sustained disease control in ErbB-dependent cancers. A large LUX-Lung 3 phase III trial recently demonstrated that afatinib is clearly superior to the most effective platinum doublet in patients with EGFR mutation-positive lung cancer . Thus, trials testing the potential efficacy of afatinib for reversible EGFR-TKI resistant NSCLCs are ongoing.
Anti-metabolite drugs, such as the fluoropyrimidine anti-cancer agent 5-fluorouracil (5-FU) and pemetrexed, have been used worldwide for chemotherapy with several types of solid tumor. Enzymes that participate in the pyrimidine metabolic pathway, including thymidylate synthase (TS), orotate phosphoribosyltransferase (OPRT), and dihydropyrimidine dehydrogenase (DPD), play an important role in FU sensitivity . For pemetrexed, high TS has been shown to be correlated with resistance based on clinical and cell culture studies . DPD is the initial enzyme in the pyrimidine catabolic pathway, and about 80 % of administered FU is rapidly catabolized in the liver [16–18]. Previously, the use of FU was thought to be inappropriate for lung cancer therapy, because the lung contains high levels of DPD, which is known to degrade FU. However, some DPD inhibitory fluoropyrimidines (DIF) have been developed which avoid the problem of degradation by DPD [19–22].
In 2007, Suehisa and colleagues showed that the IC50s of EGFR mutant cells to FU were higher than those of wild-type cells, indicating that EGFR wild-type cells are more sensitive to FU than mutant cells . In our previous immunohistochemical staining for DPD in NSCLC specimens, high DPD expression was significantly correlated with EGFR mutation status and adenocarcinoma with a lepidic pattern . Cell-based and histological studies led us to believe that EGFR mutation status might affect the sensitivity to FU due to high DPD expression in cells. Because EGFR-mutated NSCLC shows high DPD expression while EGFR wild-type shows low DPD expression, which correlate with EGFR-TKI and 5-FU sensitivity, we considered that there is a biological rationale for studying the interplay between EGFR mutation status and DPD expression for drug selection and personalized chemotherapy.
Accordingly, there are some molecular clues that explain the correlation between the EGFR cascade and DPD expression. DPYD, the DPD gene, has two transcriptional regulatory regions, and the binding of transcription factor specificity protein 1 (Sp1) to the DPYD promoter region is implicated in DPD constitutive expression [25, 26]. Lee and colleagues reported that Sp1 is present downstream of the EGFR-ERK1/2 signal cascade . These studies indicate the possibility that Sp1 intermediates the EGFR-ERK1/2 signal cascade and DPD expression.
In the present study, we examined the signaling cascade from EGFR to DPD in vitro. To examine signal cascade regulation, we treated NSCLC cell lines with EGFR signal activator (EGF) or inhibitors (gefitinib, mithramycin A). In addition, we investigated whether EGFR mutation status affects the EGFR signal cascade, Sp1 regulation, and DPD expression.
Gefitinib was purchased from Tocris Bioscience (Bristol, UK). Mithramycin A, a specific Sp1 transcription factor inhibitor, was obtained from SERVA Electrophoresis GmbH (Heidelberg, Germany). EGF and antibodies against ERK1/2, pERK1/2 (Phospho-Thr202/Tyr204), Sp1, and DPD were purchased from Cell Signaling (Beverly, MA, USA). β-actin (loading control) was from Abcam (Cambridge, UK).
Lung cancer cell lines and culture conditions
Human lung adenocarcinoma cell line PC9 (exon19 E746-A750) was obtained from Immuno-Biological Laboratories (Gunma, Japan). NCI-H1975 (exon21 L858R, T790M), NCI-H1437 (wild-type), and NCI-H1299 (wild-type) were obtained from the American Type Culture Collection (Manassas, VA, USA). HCC827 was kindly provided by Dr. Isamu Okamoto (Kyushu University Hospital). These cell lines were incubated in a humid atmosphere containing 95 % air and 5 % CO2 in Roswell Park Memorial Institute (RPMI) media (Invitrogen Japan, Tokyo, Japan). The media contained 10 % fetal bovine serum, 1 % penicillin-streptomycin (Nacalai Tesque, Kyoto, Japan), and 2 mM L-glutamine (Invitrogen Japan).
Quantitative polymerase chain reaction and mRNA expression
RNA in cultured cells was extracted using an RNeasy Mini Kit (QIAGEN, Tokyo, Japan), and cDNA was produced using PrimeScript RT Master Mix (Takara, Shiga, Japan). The sequences of PCR primers for mRNA in DPD, Sp1, and β-actin were as follows: DPD forward, 5’-GTTGTGGCTATGATTGATGA-3’, and reverse, 5’-ATTCACAGATAAGGGTACGC-3’; Sp1 forward, 5’-TTGAAAAAGGAGTTGGTGGC-3’, and reverse, 5’-TGCTGGTTCTGTAAGTTGGG-3’; β-actin forward, 5’-GCAAAGACCTGTACGCCAAC-3’, and reverse, 5’-CTAGAAGCATTTGCGGTGGA-3’. PCR reactions were performed with 20 ng of cDNA with LightCycler 480 SYBR Green I Master (Roche Molecular Biochemicals, Indianapolis, IN, USA). Quantitative RT-PCR was performed on a Roche LightCycler 480 system (Roche Molecular Biochemicals). Quantification data were analyzed with the LightCycler analysis software (Roche Molecular Biochemicals).
Western blot analysis
Nuclear Extract Kit (Active Motif, Carlsbad, CA, USA) was used to collect whole cell lysates. Proteins were fractionated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using 8 % gradient gels. The protein was blotted onto a polyvinylidene difluoride membrane. After blocking with Blocking One-P (Nacalai Tesque) for 20 min, the membrane was incubated overnight at 4 °C with primary antibodies against ERK1/2, pERK1/2, Sp1, DPD, and β-actin (loading control), followed by horseradish peroxidase-conjugated goat anti-rabbit IgG (Amersham, Buckinghamshire, UK). Immunolabeled protein was visualized using a Luminescent Image Analyzer LAS-1000plus (Fujifilm, Tokyo, Japan) after incubation with Chemi-Lumi One Super (Nacalai Tesque).
To examine the relationship between DPD expression and the EGFR signaling cascade, we administered varying concentrations of EGF (0 to 10 ng/ml). After we grew NSCLC cells to 80 % confluence, culture medium was replaced with serum-free medium, and we then administered each concentration of EGF. After additional incubation at 37 °C for 20 min, cell lysates were extracted.
Growth inhibition assay
The growth inhibitory activities of gefitinib and mithramycin A were evaluated by the cell proliferation reagent WST-1 (Roche Diagnostic GmbH, Mannheim, Germany). NSCLC cell lines were seeded in 96-well plates at a density of 105/well with culture medium for 24 h. The cells were exposed to various concentrations of FU and gefitinib/mithramycin A for another 24 h at 37 °C in a 5 % CO2 atmosphere. After that, WST-1 was added to each well and incubated for 2 h at 37 °C before measuring absorbance at 490 nm with a Multiskan JX Spectrum instrument (Thermo Labsystems, Boston, MA, USA).
Sp1 DNA binding assays
Cells were treated by gefitinib and mithramycin A, and nuclear proteins were extracted. Ten micrograms of nuclear extract were examined for Sp1 DNA binding activity by using a Trans AM Sp1 Kit (Active Motif), and control and treatment groups were compared. The absorbance was measured at 450 nm by a Multiskan JX Spectrum instrument (Thermo Labsystems).
Apoptosis assay by DNA fragmentation
Apoptosis was evaluated by enzyme-linked immunosorbent assay (ELISA) using a Cell Death Detection ELISAPlus Kit (Roche Applied Science, Mannheim, Germany). The amounts of mononucleosomes and oligonucleosomes generated from the apoptotic cells were quantified using monoclonal antibodies directed against histones and DNA by ELISA. Absorbance was measured at 405 nm by a Multiskan JX Spectrum instrument (Thermo Labsystems).
Data from WST-1 assays and real-time RT-PCR are expressed as means ± S.D. The statistical significance of differences among the five cell lines was examined by Tukey-Kramer analysis. Student’s t-test and Dunnett’s multiple comparison were used to analyze associations between the control and experimental groups in each cell line. For all experiments, a two-sided p-value less than 0.05 was considered statistically significant. All experiments were performed in triplicate.
EGFR signal cascade regulation on DPD protein expressions
To elucidate the relationship between the EGFR signal cascade and DPD expression, we first administered varying concentrations of EGF to PC9 cells (exon19 E746-A750). Western blotting showed EGF administration induced the phosphorylation of ERK1/2 and the expressions of Sp1 and DPD were increased dose-dependently (Fig. 1a). Second, we suppressed EGFR signal cascade by gefitinib, an EGFR-TKI. Western blotting showed that phosphorylations of ERK1/2 were induced by EGF stimulation and were suppressed rapidly by gefitinib, and EGF-induced expressions of both Sp1 and DPD were also suppressed in a time-dependent manner (Fig. 1b). To find out whether a reduction of Sp1 transcriptional activity affected DPD expression, PC9 cells were treated with mithramycin A, which is an inhibitor of Sp1. Western blot analysis showed that mithramycin A inhibited both Sp1 and DPD protein levels; however, the upstream signaling pathways, including ERK1/2 and pERK1/2, were not suppressed (Fig. 1c).
Effect of EGFR-TKI and mithramycin a on Sp1 transcription activity
To test the effect on Sp1 transcriptional activity, PC9 cells were treated with gefitinib and mithramycin A. Extracted nuclear protein was examined for its Sp1 DNA binding activity by using a Trans AM Sp1 Kit. Sp1 transcription activity was suppressed compared with the baseline activity level using the two drugs (p < 0.05) (Fig. 1d).
Comparison of the EGF effect in EGFR-mutated and -non-mutated NSCLC cell lines
To compare the effect of EGF in differential mutant types of NSCLC cell lines, EGF of 10 ng/ml was administrated to each cell line for 20 min (Fig. 2a). In EGFR mutant NSCLC cell lines (PC9, HCC827, and H1975), DPYD mRNA levels were significantly increased after EGF administration (p < 0.05). On the other hand, DPDY mRNA levels of EGFR in the wild-type cell lines (H1437, H1299) were not influenced by EGF treatment.
Comparison of the Gefitinib or mithramycin a effects in EGFR-mutated and -non-mutated NSCLC cell lines
We next investigated the effects of signal cascade inhibitors gefitinib and mithramycin A in EGFR-mutated and -non-mutated NSCLC cell lines. NSCLC cell lines were treated with gefitinib (1 μM) or mithramycin A (50 nM) for 24 h followed by stimulation with 10 ng/ml EGF for 20 min. As shown in Fig. 2b, gefitinib treatment suppressed EGF-induced ERK1/2 phosphorylation and both Sp1 and DPD expression only in gefitinib-sensitive NSCLC cell lines PC9 and HCC827. H1975 has an acquired resistance mutation, T790M, against gefitinib treatment.
Figure 2c shows that ERK1/2 and pERK1/2 upstream signals of the EGFR cascade were not affected by mithramycin A. Interestingly, Sp1 and DPD were inhibited only in EGFR mutant cells.
Comparison of apoptosis after treatment with Gefitinib/mithramycin a in EGFR-mutated and -non-mutated NSCLC cell lines
To evaluate the effect of gefitinib and mithramycin A on cellular apoptosis, we treated cells with gefitinib (1 μM) and mithramycin A (50 nM) for 24 h. Extracted cell lysates were evaluated by ELISA using a Cell Death Detection ELISAPlus Kit. In wild-type cells (H1299, H1437) the inhibitors had little effect on apoptosis. In contrast, the apoptotic reaction increased in EGFR-mutated cell lines treated with gefitinib, except cell line H1975 with the T790M mutation. Mithramycin A increased apoptosis in all EGFR-mutated cell lines (Fig. 3).
Comparison of the growth inhibition after combination treatment with FU and Gefitinib/mithramycin a in EGFR-mutated and -non-mutated NSCLC cell lines
To elucidate the effect of gefitinib or mithramycin A with FU in each cell line, we treated cells with combinations of FU (10 μM) and gefitinib (1 μM) or mithramycin A (50 nM). In PC9 and HCC827 cells, the levels of cell viability were significantly lower in the combination treatments including gefitinib and mithramycin A compared with FU treatment alone (Fig. 4). In H1975 cells, which have the T790M mutation, the IC50 values were lower only for the combination of mithramycin A and FU. The other two wild-type cell lines showed no differences when combining drugs. Cell viabilities using 5-FU, gefitinib, and mithramycin A were not different from the combination of two drugs (5-FU and gefitinib, or 5-FU and mithramycin A).
The present study clearly showed crosstalk among the EGFR cascade, transcription factor Sp1, and DPD expression in NSCLC cell lines. Using PC9 cells, EGF administration significantly increased DPD protein levels in a dose-dependent manner. Accordingly, gefitinib, an EGFR-TKI, inhibited the phosphorylation of ERK1/2 and decreased ERK1/2, Sp1, and DPD protein levels. The regulation of DPD by the above-described EGFR signal induction and inhibition indicated that the EGFR signal cascade directly regulates DPD expression. On the other hand, mithramycin A, a G-C specific DNA binding drug that can bind the consensus sequence of the Sp1 binding element , decreased Sp1 and DPD protein levels without inhibiting the phosphorylation and protein levels of ERK1/2. Therefore, we assessed that Sp1 is a principal candidate for the EGF-induced transcriptional regulator of DPD.
The activation of EGFR to the DPD cascade is different between EGFR-mutated and -non-mutated cell lines; EGFR mutant cells cause both ligand-independent and ligand-dependent activation of Sp1 to DPD signals. Consistent with a report by Sordella and colleagues showing that the receptor and downstream signaling are constitutively activated only in EGFR mutant cells , both Sp1 and DPD proteins were increased in EGFR-mutated cell lines compared to the wild-type under normal conditions (Fig. 2a). In addition, EGF administration increased DPYD mRNA expression only in EGFR-mutated cells. These results support the theory that EGF treatment induces higher and more consistent activation in mutant EGFRs than in wild-type EGFRs in NSCLC cell lines [1, 30]. Consistently, western blot analysis showed that gefitinib decreased ERK1/2 signaling with the suppression of the protein levels of Sp1 and DPD only in EGFR-mutated cells (Fig. 2b, c). In addition, the usage of mithramycin A showed that DPD suppression only occurred in EGFR-mutated cells, but not in wild-type cells. The two drugs also increased apoptosis in EGFR mutant cell lines (Fig. 3).
In this study, we examined H1975, another EGFR-mutated cell line that contains the T790M mutation and is resistant to gefitinib treatment (Additional file 2: Table S1). As expected, in western blot analysis, gefitinib did not decrease the DPD expression. Instead, mithramycin A clearly inhibited Sp1 and DPD expressions. Accordingly, in drug combination assays, gefitinib and FU showed additive anticancer effects in EGFR-mutated PC9 cells, but not in EGFR-resistant H1975 cells. On the other hand, mithramycin A and FU showed additive anticancer effects in all EGFR-mutated cells regardless of the T790M mutation.
The present results elucidated a relationship between clinical outcomes and the biology of EGFR-mutated NSCLC. First, in our previous histopathological study, we showed that adenocarcinoma in situ, previously classified as bronchioloalveolar carcinoma, has significantly higher EGFR mutation frequency and DPYD mRNA levels than other histological types . The presently identified signal regulation supports our previous proposal that invasive adenocarcinoma and adenocarcinoma in situ might have different biological properties due to different EGFR signal cascade regulation and DPD activity . Second, the relationship between EGFR mutation status and high DPD expression might serve as a predictor of drug sensitivity. Because DPD is a 5-FU degradation enzyme, EGFR-mutated tumors might resist DIF because of high DPD. Conversely, EGFR wild-type tumors might be sensitive to DIF because of low DPD. Consistent with this, it has been reported that EGFR wild-type tumors have higher sensitivity to uracil-tegafur than EGFR mutant tumors . Third, the present results might affect the treatment strategy for EGFR-TKI-resistant tumors. Gefitinib and 5-FU additively reduced PC9 and HCC827 cell survival, suggesting that gefitinib treatment might increase the effect of 5-FU on EGFR-TKI-sensitive tumors, possibly from DPD suppression via EGFR signal cascade inhibition. In addition, mithramycin A could enhance the 5-FU effect on EGFR-TKI-resistant tumors via direct Sp1 suppression. Mithramycin A and 5-FU-related drugs might be another option for EGFR-TKI-resistant NSCLC treatment.
The limitation of the present study is that the cis-regulatory element of DPD contains several transcription factor-binding sites aside from Sp1, including AP, Egr, and NF-kB . Fig. 4 shows that cell viability after treatment of 5-FU plus gefitinib was relatively high compared with treatment of 5-FU plus mithramycin A in PC9 and HCC827 cells. This implies the existence of some unknown transcriptional regulation present in this cascade, especially in EGFR mutant-type tumors (Additional file 1: Figure S1). Further analysis of other transcriptional regulation mechanisms might be necessary to elucidate the mechanisms of EGFR signal regulation for DPD expression. In the wild-type cell lines, 5-FU monotherapy did not affect cell survival in H1437 cells, even with low expression of DPD. In fact, the IC50 with 5-FU was higher in H1437 than in H1299, even though they have the same EGFR wild-type status (Additional file 2: Table S1). This is unsurprising because H1437 has the MEK1 exon2 mutation (Q56P substitution) , and MEK-1 signal suppression increases 5-FU sensitivity . These reports and the present results indicate that continuous MEK-1 expression in H1437 results in 5-FU resistance, possibly because of a DPD-independent mechanism in this wild-type cell line.
In conclusion, we have shown crosstalk among the EGFR cascade and Sp1 and DPD expressions in EGFR mutant cell lines. EGF-induced Sp1 up-regulation resulted in both DPYD mRNA and DPD protein expressions. Combination chemotherapy of 5-FU and EGFR-TKI additively suppressed cancer cell survival in EGFR-mutant cell lines. In particular, 5-FU and mithramycin A induced cytotoxicity in EGFR-resistant cell lines. Further studies are necessary to elucidate the detailed mechanism of EGFR cascade regulation of DPD expression, which may lead to new therapeutic strategies against NSCLC.
5-FU, 5-fluorouracil; DIF, DPD inhibitory fluoropyrimidines; DPD, dihydropyrimidine dehydrogenase; EGFR, epidermal growth factor receptor; EGFR-TKI, EGFR tyrosine kinase inhibitor; Mit A, mithramycin A; NSCLC, non-small-cell lung cancer; OPRT, ortate phosphoribosyltransferase; Sp1, specificity protein 1; TF, transcription factor; TS, thymidylate synthase
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–39.
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–500.
Thatcher N, Chang A, Parikh P, Rodriques PJ, Ciuleanu T, Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527–37.
Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005;23:2513–20.
Morita S, Hirashima T, Hagiwara K, Hida T, Sunaga K, Sugio A, et al. I-CAMP Study Group Gefitinib combined survival analysis of the mutation positives from the prospective phase II trials ASCO Annual Meeting Proceedings. J Clin Oncol. 2008;26:8101.
Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121–8.
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–8.
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open label, randomised, phase 3 study. Lancet Oncol. 2011;12:735–42.
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC):a multicenter, open-label, randomized phase 3 trial. Lancet Oncol. 2012;13:239–346.
Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung6):an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:213–22.
Pez-Ares L, Soulieres D, Melezinek I, Moecks J, Keil L, Mok T, et al. Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med. 2010;14:51–69.
Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Janne PA, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010;28:357–60.
Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase III study of afanitib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2014;15:213–22.
Maring JG, Groen HJ, Wachters FM, Uqes DR, de Vries EG. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J. 2005;5:226–43.
Zhang D, Ochi N, Takigawa N, Tanimoto Y, Chen Y, Ichihara E, et al. Establishment of pemetrexed-resistant non-small cell lung cancer cell lines. Cancer let. 2011;28:228–35.
Mattison LK, Soong R, Diasio RB. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics. 2002;3:485–92.
Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989;16:215–37.
Dobritzsch D, Schneider G, Schnackerz KD, Lindqvist Y. Crystal structure of dehydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil. EMBO J. 2001;208:650–60.
Tamura K, Okamoto I, Ozaki T, Kashii T, Takeda K, Kobayashi M, et al. Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer. Eur J Cancer. 2009;45:2132–7.
Keira K, Sunaga N, Yanagitani N, Imai H, Utsugi M, Shimizu Y, et al. A phase I dose-escalation study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer. Anticancer Drugs. 2007;18:471–6.
Kubota K, Sakai H, Yamamoto N, Kunitoh H, Nakagawa K, Takeda K, et al. A multi-institution phase I/II trial of triweekly regimen with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2010;5:702–6.
Lamont EB, Schilsky RL. The oral fluoropyrimidines in cancer chemotherapy. Clin Cancer Res. 1999;5:2289–96.
Suehisa H, Toyooka S, Hotta K. Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. J Clin Oncol. 2007;25:3952–7.
Mochinaga K, Tsuchiya T, Nagasaki T, Arai J, Tominaga T, Yamasaki N, et al. High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of NSCLC using 5-fluorouracil. Clin Lung Cancer. 2014;15:136–40.
Shestopal SA, Johnson MR, Diasio RB. Molecular cloning and characterization of the human dihydropyrimidine dehydrogenase promoter. Biochim Biophys Acta. 2000;1494:162–9.
Zhang X, Li L, Fourie J, Davie JR, Guarcello V, Diasio RB, et al. The role of Sp1 and Sp3 in the constitutive DPYD gene expression. Biochim Biophys Acta. 2006;1759:247–56.
Lee TC, Oslund KL, Thai P, Velichoko S, Fujisawa T, Duong T, et al. 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin-induced MUC5AC expression: aryl hydrocarbon receptor-independent/EGFR/ERK/p38-dependent SP1-based transcription. Am J Respir Cell Mol Biol. 2011;45:270–6.
Blume SW, Snyder RC, Ray R, Thomas S, Koller CA, Miller DM. Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dehydrofolate reductase gene in vitro and in vivo. J Clin Invest. 1991;88:1613–21.
Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305:1163–7.
Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, Zappaterra M, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. ProS Med. 2005;2:1167–76.
Marks JL, Gong Y, Chitale D, Golas B, McLellan MD, Kasai Y, et al. Novel MEK1 mutation identified by mutational analysis epidermal growth factor receptor signaling pathway in lung adenocarcinoma. Cancer Res. 2008;68:5524–8.
Urick ME, Chung EJ, Shield WP. Enhancement of 5-Fluorouracil-induced in vitro and in vivo radiosensitization with MEK inhibition. Clin Cancer Res. 2011;17:5038–47.
We thank Dr. Shinji Kondo and Tatsuo Inamine for their excellent technical assistance. The present study was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (No. 26462130).
TT, KMo, NY, KMa, and TM conceived the experiments. TT, JA, TN and KMo performed the experiments and analyzed the data together with TT, AN, KT and TN provided valuable help on the optics. TT co-wrote the paper. All authors discussed the results and commented on the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Schematic diagrams of the signal cascade of EGF-induced DPD expression of EGFR-mutated type cells. TF, transcription factor; Mit A, mithramycin A. (JPG 130 kb)
Effects of 5-FU, gefitinib, and mithramycin A on cell proliferation in NSCLC cell lines. Cells were incubated with various concentrations of 5-FU for 72 h, and cell viability was examined by WST-1 assay. The IC50 values of these drugs were calculated for each cell line. Cell viability of the control group (DMSO) was set at 100 %. Values are means from three samples from one representative experiment. (XLSX 9 kb)
About this article
Cite this article
Tominaga, T., Tsuchiya, T., Mochinaga, K. et al. Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer. BMC Cancer 16, 354 (2016). https://doi.org/10.1186/s12885-016-2392-0
- Non-small-cell lung cancer
- Dihydropyrimidine dehydrogenase
- Epidermal growth factor receptor mutation